VWM
BEAM icon

Vermillion Wealth Management’s Beam Therapeutics BEAM Stock Holding History

Vermillion Wealth Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$24 – 1634
2026
Q1 		$24 Buy
+1
New +$28 ﹤0.01% 1526

Other funds holding BEAM

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
BFS
Beacon Financial Strategies Raleigh, North Carolina $201M AUM 19.14% 1-Year Est. Return
TWM
Thrive Wealth Management Audubon, Pennsylvania $787M AUM 23.6% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

Vermillion Wealth Management's BEAM Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 1 share — an estimated $24 sold.

Vermillion Wealth Management first reported a position in BEAM in Q1 2026 and held it in 1 quarter. The position peaked at $24 in Q1 2026. 14 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 1 Beam Therapeutics share in Q2 2026, an estimated $24.
  • Vermillion Wealth Management first reported a position in Beam Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Beam Therapeutics position peaked at $24 in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.